Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India.
Indian J Tuberc
; 71 Suppl 1: S67-S71, 2024.
Article
en En
| MEDLINE
| ID: mdl-39067958
ABSTRACT
INTRODUCTION:
MDR TB is a serious global concern which is hampering TB elimination goals badly. Standardized MDR TB regimen had high default rates, more side effects and poor treatment outcomes. Bedaquiline is a newer anti-tubercular drug which has made oral regimens possible for MDR TB. We aimed to study the outcomes of MDR TB patients treated with Bdq containing regimens.METHODS:
155 patients of MDR TB on Bdq containing regimen enrolled at GMC, Patiala under NTEP from 2017 to 2020 were enrolled retrospectively.RESULTS:
Out of 155 patients enrolled, 82 (52.9 %) were cured, 31 (20 %) completed treatment, 18 (11.6 %) defaulted, 22 (14.2 %) died and 2 (0.12 %) failed treatment.CONCLUSION:
Bdq is well tolerated with very less side effects and has better outcomes as compared to standard MDR regimens which were followed earlier.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Tuberculosis Resistente a Múltiples Medicamentos
/
Centros de Atención Terciaria
/
Diarilquinolinas
/
Antituberculosos
País/Región como asunto:
Asia
Idioma:
En
Revista:
Indian J Tuberc
Año:
2024
Tipo del documento:
Article